You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

269 Results
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Regimen
Cancer Type:
Hematologic, 
Rare Diseases, 
Sarcoma
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jun 2019
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab (Adult and Pediatric) - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV Melanoma
Oct 2024
Guidelines and Advice
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Guidelines and Advice
Guidelines and Advice
Aug 2019
Guidelines and Advice
Guidelines and Advice
Apr 2019

Pages